57O Randomized double-blind phase II trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC: Primary resultsS. Peters大牛学者, S.M. Lim,A.L.O. Ortega Granados, G.D.J. Pinto, C.S. Fuentes,G. Lo Russo, M. Schenker, J.S. Ahn, M. Reck, Z. Szijgyarto, N. Huseinovic, E. Zografos, S. O’Donnell,F. de MarinisImmuno-Oncology and Technology（2022）引用 0|浏览4暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络
